Læknablaðið - 15.01.1997, Qupperneq 28

28
LÆKNABLAÐIÐ 1997; 83
9. Glazer WM, Kane JM. Depot Neuroleptic Therapy: an
Underutilized Treatment Option. J Clin Psychiatry
1992; 53: 426-33.
10. Davis JM, Barter JT, Kane JM. Antipsychotic drugs. In:
Kaplan HI, Sadock BJ, eds. Comprehensive Textbook
of Psychiatry. 5th. ed. Baltimore, Md: Williams & Wil-
kins; 1989: 1591-626.
11. Mantel N, Haenszel W. Statistical aspects of the analysis
of data from retrospective studies of disease. J Natl
Cancer Inst 1959; 22: 719-48.
12. Kane JM, Borenstein M. Compliance in the long-term
treatment of schizophrenia. Psychopharmacol Bull 1985;
21: 23-7.
13. Kane JM, Lieberman JA. Maintenance Pharmacoth-
erapy in Schizophrenia. In: Meltzer HY, ed. Psycho-
pharmacology: The Third Generation of Progress. New
York, NY: Raven Press; 1987: 1103-9.
14. Davis JM, Kane JM, Marder SR, Brauzer B, Gierl B,
Schooler N, et al. Dose Response of Prophylactic Anti-
psychotics. J Clin Psychiatry 1993; 54/Suppl. 3: 24-30.
15. Caffey EM, Diamond LS, FrankTV. Discontinuationor
reduction of chemotherapy in chronic schizophrenics. J
Chron Dis 1964; 17: 347-58.
16. Hogarty GE, Goldberg SC. Collaborative Study Group.
Drugs and sociotherapy in the aftercare of schizophrenic
patients: one-year relapse rates. Arch Gen Psychiatry
1973; 28: 54-64.
17. Hogarty GE, Goldberg SC, Schooler NR. Drugs and
sociotherapy in the aftercare of schizophrenic patients,
II: two-year relapse rates. Arch Gen Psychiatry 1974; 31:
603-8.
18. Hogarty GE. Schooler NR, Ulrich R. Fluphenazine and
social therapy in the aftercare of schizophrenic patients:
relapse analyses of a two-year controlled study of flu-
phenazine decanoat and fluphenazine hydrochloride.
Arch Gen Psychiatry 1979; 36: 1283-94.
19. Hogarty GE, Ulrich RF, Mussare F, Aristigueta N.
Drug Discontinuation Among Long-Term Successfully
Maintained Schizophrenic Outpatients. Dis Nerv Syst
1976; 37: 494-500.
20. Schooler NR, Levine J, Severe JB, Brauzer B, DiMas-
cio A, Klerman GL, et al. Prevention of Relapse in
Schizophrenia: an Evaluation of Fluphenazine Deca-
noate. Arch Gen Psychiatry 1980; 37: 16-24.
21. Hogarty GE, McEvoy JP, Munetz M, DiBarry AL,
Bartone P, Cather R, et al. Dose of Fluphenazine, Fam-
ilial Expressed Emotion, and Outcome in Schizophre-
nia. Arch Gen Psychiatry 1988; 45: 797-805.
22. Comaty JE, Janicak PG. Depot neuroleptics. Psychiatr
Ann 1987; 17: 491-6.
23. Schooler NR. Maintenance Medication for Schizophre-
nia: Strategies for Dose Reduction. Schizophrenia Bull
1991; 17: 311-24.
24. Carpenter WT, Hanlon TE, Heinrichs DW, Summerfelt
AT, Kirkpatrick B, Levine J, et al. Continuous Versus
Targeted Medication in Schizophrenic Outpatients:
Outcome Results. Am J Psychiatry 1990 147: 1138-48.
25. Herz MI, Glazer WM, Mostert MA, Sheard MA, Szy-
manski HV, Hafez H, et al. Intermittent vs Maintenance
Medication in Schizophrenia: Two Year Results. Arch
Gen Psychiatry 1991; 48: 333-9.
26. Pietzcker A, Gaebel W, Köpcke W, Linden M, Miiller
P, Muller-Spahn F, et al. Intermittent Versus Mainte-
nance Neuroleptic Long-Term Treatment in Schizo-
phrenia—2-Year Results of a German Multicenter
Study. J Psychiat Res 1993; 27: 321-39.
27. Kane JM, Rifkin A, Woerner M, Reardon G, Saranta-
kos S, Schiebel D, et al. Low-dose neuroleptic treatment
of Outpatient Schizophrenics. Arch Gen Psychiatry
1983; 40: 893-6.
28. Kane JM, Rifkin A, Woerner M, Reardon G, Saranta-
kos S, Schiebel D, et al. High Dose vs Low Dose Strate-
gies in the Treatment of Schizophrenia. Psychopharma-
col Bull 1985; 21: 533-7.
29. Burnett PL, Galletly CA, Moyle RJ, Clark CR. Low-
Dose Depot Medication in Schizophrenia. Schizophre-
nia Bull 1993; 19: 155-64.
30. Baldessarini RJ, Cohen BM, Teicher MH. Significance
of Neuroleptic Dose and Plasma Level in the Pharmac-
ological Treatment of Psychoses. Arch Gen Psychiatry
1988; 45: 79-91.
31. Tuninger E, Axelsson R, Levander S. A 3-year study of
maintenance therapy with depot neuroleptics. Clinical
characteristics and medication at study entry. Nordic J
Psychiatry 1994; 48: 409-17.
32. Inderbitzin LB, Lewine RRJ, Gloersen BA, Rosen PB,
McDonald SC, Vidanagama BP. Fluphenazine Deca-
noat: a Clinical Problem? Am J Psychiatry 1989; 146:
88-91.
33. Galletly CA. Antipsychotic Drug Doses in a Schizo-
phrenia Inpatient Unit. Aust N Z J Psychiatry 1992; 26:
574-6.
34. Remington GJ, Prendergast P, Bezchlibnyk-Butler KZ.
Dosaging Patterns in Schizophrenia with Depot, Oral
and Combined Neuroleptic Therapy. Can J Psychiatry
1993; 38: 159-61.
35. Þorsteinsson GÁ. Um aukaverkanir geðlyfja. Lækna-
blaðið 1983; 69/Suppl. 17: 31-5.
36. Lingjærde O, Ahlfors UG, Bech P, Dencker SJ, Elgen
K. The UKU Side Effect Rating Scale. Acta Psychiatr
Scand 1987; 76/Suppl. 334.
37. Marder SR. Depot Neuroleptics: Side Effects and Safe-
ty. J Clin Psychopharmacol 1986; 6/Suppl.l: 24S-29S.
38. Marder SR, Van Putten T, Mintz J, McKenzie J, Lebell
M, Faltico G, et at. Costs and Benefits of Two Doses of
Fluphenazine. Arch Gen Psychiatry 1984; 41: 1025-9.
39. Rifkin A, Quitin F, Klein DF. Akinesia. A Pooriy Rec-
ognized Drug-Induced Extrapyramidal Behavioral Dis-
order. Arch Gen Psychiatry 1975; 32: 672-4.
40. Van Putten T, May PRA. “Akinetic Depression" in
Schizophrenia. Arch Gen Psychiatry 1978; 35: 1101-7.
41. Lingjærde, O. Psykofarmaka. Den Medikamentelle Be-
handiing av Psykiske Lidelser. TANO A.S. 1988.
42. Glazer WM. Depot Fluphenazine: Risk/Benefit Ratio. J
Clin Psychiatry 1984; 45(5,sec 2); 28-35.
43. Baldessarini RJ, Cole JO, Davis JM, Gardos G, Pres-
korn SH, Tarsy D. Tardive Dyskinesia: a Task Force
Report. Washington: American Psychiatric Associ-
ation, 1980.
44. Kane JM, Jeste D, Barnes TRE, Casey DE, Cole JO,
Davis JM, et al. Report of the American Psychiatric
Association Task Force on Tardive Dyskinesia. Wash-
ington, DC: American Psychiatric Press, 1992.
45. Gerlach J, Casey DE. Tardive Dyskinesia. Acta Psy-
chiatr Scand 1988; 77: 369-78.
46. Kane JM, Woerner M, Borenstein M, Wegner J, Liber-
man J. Integrating Incidence and Prevalence of Tardive
Dyskinesia. Psychopharmacol Bull 1986; 22: 254-8.
47. Casey DE. Tardive Dyskinesia: Reversible and Irrevers-
ible. In: Casey DE, Chase TN, Christensen AV, Gerlach
J, eds. Dyskinesia-Research and Treatment. New York:
Springer-Verlag, 1985: 88-97.
48. Jeste DV, Wyatt RJ. Search of Treatment for Tardive
Dyskinesia: Review of the Literature. Schizophrenia
Bull 1979; 5: 251-93.
49. Quitkin F, Rifkin A, Gochfeld L, Klein DF. Tardive
Dyskinesia: are First Signs Reversible? Am J Psychiatry
1977; 134: 84-7.
50. Johnson DAW, Pasterski G, Ludlow JM, Street K, Tay-
lor RDW. The Discontinuance of Maintenance Neuro-